X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 93.7 35.2 266.4% View Chart
P/BV x 13.3 9.1 147.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CADILA HEALTHCARE
Mar-16
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,285454 282.8%   
Low Rs634305 208.2%   
Sales per share (Unadj.) Rs189.696.1 197.3%  
Earnings per share (Unadj.) Rs-0.214.9 -1.4%  
Cash flow per share (Unadj.) Rs3.817.8 21.6%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.652.3 131.3%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x5.13.9 128.2%   
Avg P/E ratio x-4,712.725.5 -18,471.8%  
P/CF ratio (eoy) x249.621.3 1,172.4%  
Price / Book Value ratio x14.07.3 192.6%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m23,988388,458 6.2%   
No. of employees `0001.615.4 10.1%   
Total wages/salary Rs m1,60513,317 12.0%   
Avg. sales/employee Rs Th3,040.26,371.1 47.7%   
Avg. wages/employee Rs Th1,029.2862.4 119.3%   
Avg. net profit/employee Rs Th-3.3986.1 -0.3%   
INCOME DATA
Net Sales Rs m4,74098,376 4.8%  
Other income Rs m92941 9.8%   
Total revenues Rs m4,83299,317 4.9%   
Gross profit Rs m-13023,829 -0.5%  
Depreciation Rs m1013,022 3.3%   
Interest Rs m0486 0.0%   
Profit before tax Rs m-13921,262 -0.7%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m139-25 -555.6%   
Tax Rs m55,716 0.1%   
Profit after tax Rs m-515,226 -0.0%  
Gross profit margin %-2.724.2 -11.3%  
Effective tax rate %-3.726.9 -13.6%   
Net profit margin %-0.115.5 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72644,376 6.1%   
Current liabilities Rs m2,43534,071 7.1%   
Net working cap to sales %6.110.5 58.7%  
Current ratio x1.11.3 86.0%  
Inventory Days Days7454 137.0%  
Debtors Days Days4162 65.4%  
Net fixed assets Rs m1,03547,896 2.2%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m94248,746 1.9%   
Net worth Rs m1,71653,519 3.2%   
Long term debt Rs m08,964 0.0%   
Total assets Rs m4,156100,163 4.1%  
Interest coverage xNM44.7-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.11.0 116.1%   
Return on assets %-0.115.7 -0.8%  
Return on equity %-0.328.4 -1.0%  
Return on capital %034.3 0.0%  
Exports to sales %5.745.3 12.6%   
Imports to sales %6.55.9 108.9%   
Exports (fob) Rs m27044,537 0.6%   
Imports (cif) Rs m3065,838 5.2%   
Fx inflow Rs m37544,881 0.8%   
Fx outflow Rs m4709,069 5.2%   
Net fx Rs m-9635,812 -0.3%   
CASH FLOW
From Operations Rs m-819,938 -0.0%  
From Investments Rs m-146-9,039 1.6%  
From Financial Activity Rs m862-9,527 -9.1%  
Net Cashflow Rs m7091,372 51.6%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS